Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson B, Dahl O, Rosencher N, Kurth A, et al. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson B, Dahl O, Rosencher N, Kurth A, et al.
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • From 1999-2000, average blood pressures for Americans age 40 and older would have been 10-13% higher without antihypertensive drug therapy.  
  • Compared to standard coverage, 3 years of full coverage for prevention medications will reduce mortality and reinfarction rates and will save $5,974 per patient.  
  • Mortality rates in the first 3 months after a heart attack have fallen by about 75%.  
  • In 2001, 86,000 more premature deaths from cardiovascular disease (50,000 men and 36,000 women) would have occurred among Americans age 40 and older without antihypertensive drug therapy.  
  • If antihypertensive medication were widely used, it would result in an estimated increase in life expectancy (averaged over the entire population) of 0.5 years in men and 0.4 years in…